Effect of L-000845704, an αVβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women von Murphy, M. G., Cerchio, K., Stoch, S. A., Gottesdiener, K., Wu, M., Recker, R.

Volltext

Acute Alertness-Promoting Effects of a Novel Histamine Subtype-3 Receptor Inverse Agonist in Healthy Sleep-Deprived Male Volunteers von Iannone, R, Palcza, J, Renger, J J, Calder, N, Cerchio, K, Gottesdiener, K, Hargreaves, R, Dijk, D J, Boyle, J, Murphy, M G

Volltext

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporot... von MURPHY, M. G, WEISS, S, MCCLUNG, M, SCHNITZER, T, CERCHIO, K, CONNOR, J, KRUPA, D, GERTZ, B. J

Volltext

Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure von SVENSSON, J, LÖNN, L, SJÖSTRÖM, L, BENGTSSON, B.-A, JANSSON, J.-O, MURPHY, G, WYSS, D, KRUPA, D, CERCHIO, K, POLVINO, W, GERTZ, B, BOSEAUS, I

Volltext

Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults von CHAPMAN, I. M, PESCOVITZ, O. H, THORNER, M. O, MURPHY, G, TREEP, T, CERCHIO, K. A, KRUPA, D, GERTZ, B, POLVINO, W. J, SKILES, E. H, PEZZOLI, S. S

Volltext

Oral Administration of the Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults von Murphy, M. G., Bach, M. A., Plotkin, D., Bolognese, J., Ng, J., Krupa, D., Cerchio, K., Gertz, B. J.

Volltext

Treatment with the Oral Growth Hormone Secretagogue MK‐677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males von Svensson, J., Ohlsson, C., Jansson, J.‐O., Murphy, G., Wyss, D., Krupa, D., Cerchio, K., Polvino, W., Gertz, B., Baylink, D., Mohan, S., Bengtsson, B.‐Å.

Volltext

To assess the effect of ridaforolimus on the QTc interval in patients with advanced cancer von Sullivan, D., Patnaik, A., Papadopoulos, K. P., McCrea, J. B., Cerchio, K., Li, X., Stroh, M., Orford, K. W., Trucksis, M., Ebbinghaus, S., Agrawal, N., Iwamoto, M., Wagner, J. A., Tolcher, A. W.

Volltext

PHARMACOKINETICS AND FOOD INTERACTION OF MK-462 IN HEALTHY MALES von Cheng, Haiyung, Polvino, William J., Sciberras, David, Yogendran, L., Cerchio, Kristine A., Christie, Karen, Olah, Timothy V., McLoughlin, Debra, James, Ian, Rogers, J. Douglas

Volltext

Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women von Murphy, M G, Cerchio, K, Stoch, S A, Gottesdiener, K, Wu, M, Recker, R

Volltext

Effect of L-000845704, an alpha sub(V) beta sub(3) Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women von Murphy, M G, Cerchio, K, Stoch, SA, Gottesdiener, K, Wu, M, Recker, R

Volltext

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient... von Codner, Ethel, Cassorla, Fernando, Tiulpakov, Anatoly N., Mericq, M. Verónica, Avila, Alejandra, Pescovitz, Ora H., Svensson, Johan, Cerchio, Kristine, Krupa, David, Gertz, Barry J., Murphy, Gail

Volltext

Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporot... von Murphy, M. G., Weiss, S., McClung, M., Schnitzer, T., Cerchio, K., Connor, J., Krupa, D., Gertz, B. J.

Volltext

Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporot... von Murphy, M. G., Weiss, S., McClung, M., Schnitzer, T., Cerchio, K., Connor, J., Krupa, D., Gertz, B. J.

Volltext

Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group von Murphy, M G, Bach, M A, Plotkin, D, Bolognese, J, Ng, J, Krupa, D, Cerchio, K, Gertz, B J

Volltext

Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure 1 von Svensson, J., Lönn, L., Jansson, J.-O., Murphy, G., Wyss, D., Krupa, D., Cerchio, K., Polvino, W., Gertz, B., Boseaus, I., Sjöström, L., Bengtsson, B.-Å.

Volltext

Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure1 von Svensson, J, Lönn, L, Jansson, J.-O, Murphy, G, Wyss, D, Krupa, D, Cerchio, K, Polvino, W, Gertz, B, Boseaus, I, Sjöström, L, Bengtsson, B.-Å

Volltext

D4Pharmacokinetics Of Extended Release Diltiazem In Elderly Subjects von Polvino, WJ, Porras, A, Laskin, O, Cerchio, K, Chiou, R., Han, R, Hoagland, V, Lasseter, K

Volltext

Pharmacokinetics of extended release diltiazem in elderly subjects von Polvino, WJ, Portas, A, Laskin, O, Cerchio, K, Chiou, R., Han, R, Hoagland, V, Lasseter, K

Volltext

D5Effect Of Food On The Pharmacokinetics Of Extended Release Diltiazem von Cerchio, K, Seibold, J, Porras, AG, Chiou, R, McNamara, M, Laskin, O, Polvino, WJ

Volltext